The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 24, 2009
Filed:
Dec. 23, 2004
Miriam Frieden, Kobenhavn N, DK;
Jens B. Hansen, Vaerlose, DK;
Henrik Orum, Vaerlose, DK;
Majken Westergaard, Birkerod, DK;
Charlotte A. Thrue, Residence Not Provided, DK;
Miriam Frieden, Kobenhavn N, DK;
Jens B. Hansen, Vaerlose, DK;
Henrik Orum, Vaerlose, DK;
Majken Westergaard, Birkerod, DK;
Charlotte A. Thrue, Residence Not Provided, DK;
Santaris Pharma A/S, Horsholm, unknown;
Abstract
The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position No. 1459 (5') to No. 1476 (3′) of the human Bcl-2 mRNA, said target binding domain having the formula: 5′-[(DNA/RNA)-(LNA/LNA*)-(DNA/RNA/LNA*)-(LNA/LNA*)-(DNA/RNA)]-3′ and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (—O—P(O,S)—O—). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.